The granted claims of the patents include the class of selective alpha-4-beta-two compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder
Suven Life Sciences has received one product patent from Australia (2010337837), two product patents from Japan (5536227, 5588018) and one product patent from Hong Kong (1174913) corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2030.
The granted claims of the patents include the class of selective alpha-4-beta-two compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of 19 granted patents from Australia, 14 granted patents from Japan and 15 granted patents from Hong Kong.
These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.
Comments are closed.